Cargando…

Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion

SIMPLE SUMMARY: Recently, innovative gene therapy has been developing toward functional restoration by gain of function or gene correction. Hemophilia is a representative genetic disorder with many human patients and is considered a candidate disease for gene therapy. The most frequent severe hemoph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Jeong Pil, Song, Dong Woo, Lee, Jeong Hyeon, Lee, Geon Seong, Yeom, Su Cheong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389204/ https://www.ncbi.nlm.nih.gov/pubmed/34439937 http://dx.doi.org/10.3390/biology10080704

Ejemplares similares

Factor VIII Intron 22 Inversion in Severe Hemophilia A Patients in Palestine
por: Mahmoud Abu Arra, Caesar, et al.
Publicado: (2020)

Identification of the Intron 22 and Intron 1 Inversions of the Factor VIII Gene in Iraqi Kurdish Patients With Hemophilia A
por: Abdulqader, Aveen M. Raouf, et al.
Publicado: (2020)

Frequency of Intron 22 Inversion in Severe Hemophilia A Patients
por: Ashfaq, Javeria, et al.
Publicado: (2022)

Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?
por: Sherief, Laila M., et al.
Publicado: (2020)

Positive Correlation between nNOS and Stress-Activated Bowel Motility Is Confirmed by In Vivo HiBiT System
por: Han, Jeong Pil, et al.
Publicado: (2021)

Screening of Intron 1 Inversion of the Factor VIII Gene in 130 Patients with Severe Hemophilia A from a Pakistani Cohort
por: Sattar, Azhar, et al.
Publicado: (2017)

Prominent Mutation of Intron 22 Inversion in Sporadic Hemophilia: Is It Worth the Antenatal Screening?
por: Sasanakul, Werasak, et al.
Publicado: (2022)

Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

Genome editing-mediated knock-in of therapeutic genes ameliorates the disease phenotype in a model of hemophilia
por: Lee, Jeong Hyeon, et al.
Publicado: (2022)

In vivo genome editing using 244-cis LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice
por: Han, Jeong Pil, et al.
Publicado: (2023)

In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs
por: Wu, Yong, et al.
Publicado: (2016)

Large Intron Inversions in Romanian Patients with Hemophilia A—First Report
por: Brinza, Melen, et al.
Publicado: (2023)

In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy
por: Han, Jeong Pil, et al.
Publicado: (2022)

Hemophilia A subjects with an intron-22 gene inversion mutation show CD4(+) T-effector responses to multiple epitopes in FVIII
por: Gunasekera, Devi, et al.
Publicado: (2023)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Identification of deep intronic individual variants in patients with hemophilia A by next‐generation sequencing of the whole factor VIII gene
por: Inaba, Hiroshi, et al.
Publicado: (2017)

Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab
por: Lee, Min Young, et al.
Publicado: (2023)

Mutations in Intron 1 and Intron 22 Inversion Negative Haemophilia A Patients from Western India
por: Nair, Preethi S., et al.
Publicado: (2014)

Bacterial Production of Recombinant Coagulation Factor VIII Domains
por: Bashar, Saima, et al.
Publicado: (2023)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients
por: Abrantes, João A., et al.
Publicado: (2020)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
por: Chen, Zhenping, et al.
Publicado: (2021)

Morc2a p.S87L mutant mice develop peripheral and central neuropathies associated with neuronal DNA damage and apoptosis
por: Lee, Geon Seong, et al.
Publicado: (2021)

Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
por: Chen, Zhen-Ping, et al.
Publicado: (2018)

Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A
por: Bachelet, Delphine, et al.
Publicado: (2019)

Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA
por: Russick, Jules, et al.
Publicado: (2020)

Genetic Characterization of the Factor VIII Gene in a Cohort of Colombian Patients with Severe Hemophilia A with Inhibitors
por: Doncel, Samuel Sarmiento, et al.
Publicado: (2022)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

An Implementation of Inverse Cosine Hardware for Sound Rendering Applications
por: Lee, Jinyoung, et al.
Publicado: (2023)

Binding of Factor VIII to Lipid Nanodiscs Increases its Clotting Function in a Mouse Model of Hemophilia A
por: Csencsits-Smith, Keri, et al.
Publicado: (2015)

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
por: Tiede, Andreas, et al.
Publicado: (2020)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A
por: Oh, Jisu, et al.
Publicado: (2013)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Clot stability as a determinant of effective factor VIII replacement in hemophilia A
por: Leong, Lilley, et al.
Publicado: (2017)

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
por: Lieuw, Kenneth
Publicado: (2017)

Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
por: Chen, Chun-Yu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2ok8b29edokg7rpgk7phrqffh7